The global bleeding disorders testing market was valued at USD 102.0 million in 2024. It is expected to grow from USD 109.8 million in 2025 to USD 189.7 million by 2032, registering a CAGR of 8.1% during the forecast period. In 2024, North America led the bleeding disorders testing market, accounting for 40.2% of the global share.

The global bleeding disorders testing market is experiencing steady growth, driven by rising awareness, improved diagnostic technologies, and increasing healthcare investments. Early and accurate detection of bleeding disorders has become a key focus area, especially with the growing burden of conditions such as hemophilia and von Willebrand disease. Advancements in laboratory testing, along with the expansion of healthcare infrastructure across emerging regions, are further supporting market development. As diagnostic capabilities continue to evolve, the bleeding disorders testing market is expected to witness continued expansion over the coming years.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/bleeding-disorder-testing-market-106908**

Market Segmentation

• The bleeding disorder testing market is segmented by test type, including complete blood count (CBC), factor assays, PT, APTT, and fibrinogen tests.
• Based on disorder type, the bleeding disorder testing market is categorized into hemophilia A, hemophilia B, von Willebrand disease, and others.
• By end user, the bleeding disorder testing market includes hospitals, diagnostic laboratories, and research institutions.
• The market also segments by technology, such as molecular diagnostics, coagulation analyzers, and immunoassays.
• Segmentation by region allows for a targeted understanding of bleeding disorder testing market performance globally.

List of Top Bleeding Disorders Testing Companies:

• Hoffmann-La Roche Ltd. (Switzerland)
• Siemens Healthcare GmbH (Germany)
• HORIBA Ltd. (Japan)
• Sysmex Corporation (Japan)
• Abbott (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Atlas Medical GmbH (Germany)
• HYPHEN BioMed (France)